On June 9, 2025, Klotho Neurosciences, Inc. entered into a Stock Purchase Agreement for the sale of Series B Preferred stock totaling $500,000. Although the specific number of shares was not disclosed, these shares are convertible into the Company's Common Stock following SEC approval. The transaction was conducted without underwriters and no sales commissions were paid. The agreement was part of a private placement relying on an exemption from registration under the Securities Act of 1933.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.